Business
PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities
R&D assessment shows the platform can incorporate different drug entities onto its sustained-release matrix, supporting long-term potential to reduce or eliminate reliance on medicated eye dropsTEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio’s proprietary drop-less, sustained-release ocular drug-delivery platform. The assessment confirmed that its sustained release, pol
About this update from Prf Technologies Ltd.
[{"type":"image","alt":"PainReform Ltd","displaySize":"","headline":null,"caption":"PainReform Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":283,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8rnf4Sfc87De6ZQ.vLH_qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a","width":283,"height":122}},"lazy":false},{"type":"text","content":"R&D assessment shows the platform can incorporate different drug entities onto its sustained-release matrix, supporting long-term potential to reduce or eliminate reliance on medicated eye drops","length":198,"tagName":"p"},{"type":"text","content":"TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio’s proprietary drop-less, sustained-release ocular drug-delivery platform. The assessment confirmed that its sustained release, polymer matrix platform can incorporate a variety of drug entities, reinforcing its long-term potential to provide greatly improved pharmacological efficiency and simplify postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops – the DROP-LESS advantage.","length":606,"tagName":"p"},{"type":"text","content":"The matrix platform successfully incorporated corticosteroids and NSAIDs—two major therapeutic drug classes routinely used after cataract surgery. The results support the technical feasibility of multi-drug potential.","length":217,"tagName":"p"},{"type":"text","content":"LayerBio’s pre-fabricated OcuRing is placed during cataract surgery via an intraocular route, enabling sustained-release drug delivery to targeted ocular tissues. By providing controlled exposure at a fraction of the total drug amount used in traditional eye-drop regimens, the platform has the potential to improve patient comfort, reduce safety risks associated with higher drop dosing and significantly enhance compliance—an important unmet need especially among elderly cataract patients.","length":492,"tagName":"p"},{"type":"text","content":"“Our assessment confirms one of the core reasons for our LayerBio investment—the underlying platform can be engin...